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a b s t r a c t
The role of cellular immune response in dengue virus infection is not yet fully understood. Only few
studies in murine models propose that CD8þ T-cells are associated with protection from infection and
disease. At the light of recent reports about the protective role of CD8þ T-cells in humans and the no
correlation between neutralizing antibodies and protection observed in several studies, a vaccine based
on cell-mediated immunity constitute an attractive approach. Our group has developed a capsid-based
vaccine as nucleocpasid-like particles from dengue-2 virus, which induced a protective CD4þ and CD8þ
cell-mediated immunity in mice, without the contribution of neutralizing antibodies. Herein we
evaluated the immunogenicity and protective efﬁcacy of this molecule in monkeys. Neither IgG
antibodies against the whole virus nor neutralizing antibodies were elicited after the antigen inocula-
tion. However, animals developed a cell-mediated immunity, measured by gamma interferon secretion
and cytotoxic capacity. Although only one out of three vaccinated animals was fully protected against
viral challenge, a viral load reduction was observed in this group compared with the placebo one,
suggesting that capsid could be the base on an attractive vaccine against dengue.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Dengue virus (DENV) infection is a major emerging disease of
tropical and subtropical countries, transmitted by the bite of an
infected mosquito, usually Stegomya aegypti. Many infections are
asymptomatic while the clinical manifestations can range from a
self-limiting febrile illness (dengue fever) to a life-threaten-
ing disease, characterized by increased vascular permeability,
thrombocytopenia, hemorrhagic manifestations and shock (den-
gue severe) (Kyle and Harris, 2008). It is estimated that nearly half
of the world population is at risk of infection and up to 50 million
people are infected each year. DENV are positive-stranded RNA
viruses belonging to the Flaviviridae family. There are four distinct
serotypes (DENV-1 to -4), which show 67–75% sequence homol-
ogy (Fu et al., 1992).
For several years, researchers have associated the generation of
neutralizing antibodies as a premise to reach protection against
DENV. However, dengue is a non-cytopathic virus that up-regulates
the surface expression of MHC-I molecules in the infected cells
(Lobigs et al., 2004), thus the cellular immune response should
constitute other important mediator of the adaptive immune
system against this pathogen. Little is known about the protective
role of cell-mediated immunity (CMI) against this pathogen. To our
knowledge, only ﬁve reports provide evidences about this issue in
the mouse model. The ﬁrst report describes the contribution of
CD8þ cells in protecting mice immunized with the Yellow fever-
dengue chimeric virus (van der Most et al., 2000). In a second
report, our group demonstrated the role of the cellular immune
response against DENV-2 after infection with the homologous virus
in mice (Gil et al., 2009). The third report has also shown that
the immunization of mice with four CD8þ T cell epitopes from
DENV-2, which are immunodominant in this animal model,
enhances viral clearance (Yauch et al., 2009). Finally our group
published new evidence, using recombinant nucleocapsid-like
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particles from DENV-2 (NLPs-2). This antigen induced IFN-γ-
secreting and cytolytic CD4þ and CD8þ cells with protective
capacity, without the contribution of neutralizing antibodies
(Gil et al., 2012). Further studies on CMI to better understand the
immunopathology of dengue and the immunogenicity of vaccine
candidates are required.
In the present work, the immunogenicity of the recombinant
NLPs-2 was evaluated in Vervet monkeys [Chlorocebus (formerly
Cercopithecus) aethiops sabaeus] to have another evidence of the
protective role of the neutralizing antibodies independent immu-
nity against DENV.
Results
Recombinant NLPs-2 do not induce antiviral and neutralizing
antibodies in monkeys
To evaluate the immunogenicity and protective efﬁcacy of
NLPs-2 in monkeys, animals were divided in two groups. One
group received the NLPs-2 formulation and the second group
acted as a negative control. Placebo group was immunized with
the same quantity of ODN 39M contained in the formulation of
NLPs-2 and alum. All animals received four doses at days 0, 60, 120
and 180.
The kinetics of anti-capsid antibody response was determined.
As shown in Fig. 1A, immunized animals developed anti-capsid
antibodies after the ﬁrst dose. Antibody titers increased after
the second and third doses to a geometric mean titer (GMT) of
48000. Administration of the fourth dose increased the GMT to
20,000 for NLPs-2-immune animals.
The antibody response against the whole DENV-2 was also
measured by an indirect ELISA system. As expected, monkeys
receiving the NLPs-2 or placebo did not exhibit anti-virion anti-
bodies at any of the time points analyzed before challenge
(Fig. 1B). Also, the kinetics of neutralizing antibodies was mea-
sured by PRNT, using the strain SB8553 of DENV-2 and the Vero
cell line. None of the animals receiving the NLPs-2 developed
detectable neutralizing antibodies at any of the time points tested
before challenge (Fig. 1C). However, all animals developed
neutralizing antibodies after viral challenge.
Recombinant NLPs-2 induce IFN-γ-secreting and cytotoxic cells
against DENV-2 in monkeys
Peripheral blood mononuclear cells (PBMCs) from the immu-
nized monkeys, isolated in four distinct time points, were stimu-
lated with infective DENV-2 SB8553 to measure IFN-γ secretion.
Fifteen days after the fourth dose, PBMCs from all NLPs-2-immune
animals secreted the antiviral cytokine (M2072, 80.3 pg/mL; M2126,
367.4 pg/mL and M2048, 126.5 pg/mL). However, on challenge day
only two out three monkeys (M2072 and M2126) immunized with
NLPs-2 showed a positive response, with concentration of IFN-γ of
123.9 pg/mL and 178.5 pg/mL, respectively (Fig. 2A). Interestingly,
PBMCs collected after challenge from all the animals immunized
with NLPs-2 secreted high levels of IFN-γ (M2072, 345.8 pg/mL;
M2126, 197.7 pg/mL and M2048, 582.7 pg/mL). At the same time-
point, no secretion of IFN-γ was detected in the placebo group.
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Fig. 1. Kinetics of the humoral immune response induced in monkeys by NLPs-2. (A) IgG antibodies against the recombinant protein, as measured by ELISA. Flat-bottomed
96-well plates were coated with the puriﬁed capsid protein (5 μg/mL). Serially diluted samples from sera (starting at 1:50) were assayed and detected with anti-monkey IgG-
peroxidase conjugate (B) IgG antibodies against DENV-2, as measured by ELISA. Flat-bottomed 96-well plates were coated with the monoclonal antibody 4G2 (5 μg/mL).
Serially diluted samples from sera (starting at 1:50) were assayed and detected with anti-monkey IgG-peroxidase conjugate. In both cases, data represent the mean7SD of
two independent experiments. Animals were considered positive when IgG titers were 41/50 (C) Titers of neutralizing antibodies, measured by plaque reduction
neutralization test (PRNT), in Vero cells against DENV-2 SB8553 strain. Neutralizing antibody titers are the highest serum dilution which resulted in a 50% reduction in the
number of plaques produced by DENV-2. Responders were considered when titers 41/10. Data represent the means of two independent experiments. Black arrows indicate
days of immunization with the different formulations; the gray arrow indicates day of challenge. The dashed line indicates the cutoff value.
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The cytotoxic capacity of antigen-induced memory cells was
also determined, in 48 h in vitro lactate dehydrogenase (LDH). As a
result, signiﬁcant in vitro cytotoxicity was detected in the PBMCs
isolated from two NLPs-2-immune animals (M2126, 22.7% and
M2048, 25.6%) on challenge day. No cytotoxic response was
detected in the placebo group (M2018, 4.5%; M2122, 3.3%; and
M2151, 2.6%) (Fig. 2B).
The cell-mediated immunity induced by NLPs-2 in monkeys reduce
signiﬁcantly the viral load after DENV-2 challenge
To assess the protective efﬁcacy of the recombinant vaccine
candidate, all animals were challenged by subcutaneous route
with 103 pfu of DENV-2 SB8553. Blood was collected daily during
10 days to detect viremia. The presence of virus in serum samples
was determined by plaque assay, inoculating 0.13 mL of undiluted
serum onto Vero cell. As shown in Fig. 3A, control animals
developed viremia with a mean duration of four days and max-
imum viral loads of 102.6 pfu/mL, 101.5 pfu/mL and 102.4 pfu/mL. In
turn, variable levels of viremia were detected in the group
immunized with NLPs-2 (Fig. 3B). Animal M2072 had four days
of viremia with a maximum virus titer of 101.9 pfu/mL, whereas
monkey M2126 exhibited three days of viremia with maximum
virus titer of 101.6 pfu/mL. Monkey M2048 was completely pro-
tected. However, our results revealed a signiﬁcant reduction of the
viremia in NLPs-2-immune group on days four, ﬁve and six post-
challenge (p¼0.049, p¼0.033, p¼0.016, respectively) (Fig. 3C).
A summary combining the animal features and viremia after
challenge is showed in Table 1. A relation between age, sex,
weight and viremia (magnitude and duration) was not found.
Discussion
The capsid protein is an attractive viral region for developing a
vaccine candidate against dengue due to three key issues: it
contains CTL epitopes for humans (Gagnon et al., 1996, 1999); it
can be produced in Escherichia coli as a recombinant protein (Jones
et al., 2003); and it can act as adjuvant for other viral regions, as
previously described for other viral capsids and for the capsid
protein of DENV-2 (Lazo et al., 2010, 2012).
This work is a continuation of previously published experi-
ments conducted in mice with the NLPs-2. In the present study,
they were produced by addition of 3.4 μg of ODN M39 to the
recombinant capsid protein to cause 100% of aggregation. The
conditions for aggregation were similar to those previously used in
experiments in mice with successful results (Gil et al., 2012). For
these experiments, the ODN M39 was selected based on previous
evaluations where this speciﬁc sequence induced the highest CMI
in mice (unpublished data). Theoretically, this ODN contains CpG
motifs that activate cells in mice, monkeys and humans (Krug et
al., 2001; Verthelyi et al., 2001), suggesting intrinsic adjuvant
properties that along with its aggregating function could play a
role in vaccine efﬁcacy.
Here, we evaluated the immunogenicity and protective capa-
city of NLPs-2 in vervet monkeys. Although, the more common
species employed for dengue vaccine testing have been rhesus
(Macaca mulatta) and cynomolgus (Macaca fascicularis), green
monkeys offer a suitable and less expensive alternative species.
Also, they are similar to rhesus macaques in behavior, physiology
(Coe et al., 1992; Higley et al., 1996) and proximity to humans
(Page and Goodman, 2001; Raaum et al., 2005), and may pose
fewer health and safety risks (Baulu et al., 2002).
As expected, NLPs-2 did not induce IgG antibodies against the
whole virus neither neutralizing antibodies. The antibodies gen-
erated were only directed to the capsid protein. In the virion, it is
well known that none of the regions of the viral nucleocapsid is
exposed on the surface (Kuhn et al., 2002; Mukhopadhyay et al.,
2005) and therefore they are not likely to interact with B cells
during the viral infection. This lack of anti-virion antibodies
induction upon vaccination with NLPs is a key point for the safety
of the vaccine since the ADE phenomenon, associated to anti-
bodies against the Envelope and prM proteins, would not occur.
The evaluation of CMI was the principal arm of the immune
systemwith a potential role in this study. CMI was assessed by two
methods: IFN-γ secretion and LDH release (a surrogate of cytotoxic
activity) from in vitro-stimulated PBMCs. PBMCs from animals
receiving NLPs-2 secreted signiﬁcant levels of IFN-γ after stimula-
tion with the virus in the time-points tested. Recently, it have been
suggested that memory natural killer cells could play a role in
protection against secondary DENV infection in mice (Zompi et al.,
2012). However, whether T-cell and/or innate lymphoid cells,
which include natural killer cells, are involved in the IFN-γ
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Fig. 2. Cell-mediated immune response against DENV-2 induced in monkeys by NLPs-2. Culture supernatants from mock-treated or DENV-2 SB8553-infected PBMCs from
individual animals of all groups were tested on days 180, 195, 210 and 240. (A) Concentration of IFN-γ, as measured by ELISA. (B) Cytotoxicity, as measured by the lactate
dehydrogenase assay. In all cases, data represent mean7SD. Numbers above the plots mean the ratio of responders/total. The dashed line indicates the cutoff value
determined as twice the average values of the placebo animals.
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secretion and cytotoxic activity, induced by NLPs-2 in monkeys,
remain as unanswered response.
Interestingly, one month after challenge all animals of the
NLPs-2 group were positive with IFN-γ-secreting PBMCs whereas
no secretion of IFN-γ was detected in the placebo group. These
differences between the two groups indicate a successful priming
of the CMI upon immunization with the protein. On the other
hand, measurement of LDH release at the day of challenge
revealed a functional cytolytic activity upon virus stimulation in
two monkeys immunized with NLPs-2.
The immunogenicity of the protein tested was reﬂected in the
partial protection obtained. It is worth noting the high antibody
response detected in monkey M2048 after challenge, as measured
both by ELISA and PRNT. The fact that this monekys was com-
pletely negative by these test after the administration of NLPs-2,
means that some non-detectable priming of the immune system
was induced by NLPs-2, which enhanced the novo antibody
production upon virus infection. This priming effect was not
measured by the IFN-γ secretion tested before challenge probably
because of the sensitivity of this technique, but it was detected by
LDH test. These results suggest that a Th1 cells induced by NLPs-2
could help to the naive B cells upon challenge, allowing a rapid
efﬁcient antibody-response that protected the monkey against
challenge.
The results obtained with the NLPs-2-immunized animals are,
to our knowledge, the ﬁrst evidence in monkeys about the role of
independent neutralizing antibody immunity in protection against
dengue. This is in accordance with evidences from experiments
conducted during the last decade, indicating the protective role of
CMI against dengue in different mouse models (Gil et al., 2009;
Yauch et al., 2010, 2009). Furthermore, published results suggest a
protective role for IFN-γ in dengue infected humans previously
vaccinated with an experimental vaccine based on attenuated
virus. The authors of this work demonstrated solid protection
after challenge of one volunteer that had undetectable neutraliz-
ing antibodies but a potent CMI, as measured by IFN-γ secretion
upon stimulation of PBMCs collected at the day of challenge
(Gunther et al., 2011). In addition, a very recent study propose
an HLA-linked protective role of CD8þ T-cells response in primary
and secondary natural infection (Weiskopf et al., 2013).
The protection obtained in this work was partial since only a
reduction of viral load was detected. Although, the qRT-PCR could
be another alternative to conﬁrm dengue viremia in monkeys
(McGee et al., 2008; Blaney et al., 2008), it has the disadvantage of
detection of plasmatic viral genomes from non-infective virus or
viral fragments. Because of NLPs-2 potentially induces a cell-
mediated immunity, which can only reduce the viral load, qTR-
PCR could not detect the differences on viremia between NLPs-
2-immune animals and placebo group.
Probably, the capsid protein does not contain a high quantity of
CMI epitopes for monkeys. In fact, very recently, a deep study
revealed that capsid is not the most immunodominant region for
CMI in humans since it contains one region of 4% of responders,
with high magnitude of T-cell response (Weiskopf et al., 2013).
Nowdays, the most advances and immunogenic vaccine candidate
are based on live attenuated strains, for example Chimerivax that
induces full protection against DENV in monkeys (Guy et al., 2010).
However, our approach does not have the potentiality to induce an
immunopathological antibody response. Subunit vaccines, based on
dengue envelope protein have also the same disadvantage. Recent
results point out the protective and safety role of CMI against DENV
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Fig. 3. Viremia levels detected by direct quantiﬁcation on Vero cell from the
monkey sera daily collected after challenge of the immunized animals. (A) Placebo
group. (B) NLPs-2 group. (C) Viremia of each group. In all cases, data represent the
mean7SEM of three independent experiments.
Table 1
Summary of animal features and viremia after DENV-2 challenge.
Group Monkey Agea Sex Weight (kg) Peak viremia (pfu/mL) Duration of viremia (days)
Placebo M2018 Juvenile Female 2.2 102.6 4
M2122 Juvenile Male 3.1 101.5 3
M2151 Adult Female 3.9 102.4 5
NLPs-2 M2072 Juvenile Female 2.5 101.9 4
M2126 Adult Female 3.2 101.6 3
M2048 Juvenile Female 2.3 0 0
a Juvenil: animals younger than three years old; Adult: animals older than three years old.
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(Zellweger et al., 2013; Weiskopf et al., 2013). In fact, a possible
explanation for the disappointing results of Sanoﬁ's candidate against
DENV-2 in humans (Sabchareon et al., 2012), is the lack of dengue T-
cell epitopes in the chimeric virus (Halstead, 2013).
Despite we consider that capsid protein should be enriched
with T-cell epitopes, or can be formulated with potent adjuvants to
increase the CMI response, the evidences obtained in the present
study pointed out about the contribution of independent neutra-
lizing antibody immunity in protection against dengue in mon-
keys. Additional vaccination schemes would be also assessed to
even eliminate the fourth dose administration and measure the
long lasting immunity.
A vaccine candidate against dengue based on uniquely CMI is
an attractive approach. Because of the antibody-dependent
enhancement (ADE) phenomenon associated to dengue infection,
a vaccine inducing antibodies should be carefully managed,
especially for endemic regions. In previously infected individuals
(the typical immunological status of the population in endemic
countries), the vaccine may be able to recall the previously
humoral immune response established by the primary infection
along with the induction of the novo neutralizing antibodies by
vaccination. The resultant balance of such interaction is unknown;
it would result in protection, non-protection or sensitization
against the second infecting serotype. Given this scenario, a
vaccine candidate based uniquely in the induction of CMI, will
avoid the induction of this “antibody balance” in dengue-positive
subjects, and would become in a safer vaccine. Such a candidate
would not prevent infection, but could reduce viral load and
disease severity without induction of ADE.
In conclusion, we propose that a tetravalent NLPs-based
vaccine could be a new and attractive approach to develop a
functional vaccine against dengue, which induces neutralizing
antibodies independent immunity. Nevertheless, the coverage of
NLPs-based vaccine would need to be very high as it may not
prevent continual DENV transmission in the population. While the
likelihood of transmission to a susceptible mosquito may be lower
due to the reduced viremia level, this vaccine would not provide
herd immunity that would be conferred by vaccines that prevent
infection.
Material and methods
Cells and viruses
African monkey kidney (Vero) cell were received from the
National Institute for Biological Standards and Control (NIBSC)
(NIBSC accession number: 011038). Cells were grown at 37 1C in
Eagle's minimal essential medium (MEM) supplemented with 10%
fetal bovine serum (FBS).
The following virus strains were used for antibody detection:
Hawaii (DENV-1), New Guinea C (DENV-2), H-87 (DENV-3) and
H241 (DENV-4) (Clarke and Casals, 1958). DENV-2 strain SB8553
(Kindly provided by Dr. Jane Cardosa) was used for the plaque
reduction neutralization test (PRNT). A viral stock for the challenge
study in monkeys and for the measurement of CMI was prepared
with DENV-2 strain SB8553 in Vero cells (Valdes et al., 2010).
Animals
Healthy adult Vervet monkeys (Cercopithecus aethiops sabaeus)
were obtained from the Institute of Primate Research of Nairobi
(IPR), Kenya. The study was carried out in IPR in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of Kenya. The protocol was approved by the
Committee on the Ethics of Animal Experiments of IPR (Number:
IPR20100908). Animals were maintained throughout the study in
individual cages that permitted the evaluation and patterns con-
duct according to their species, size, age and sex. They were fed
with commercial monkey chow, supplemented with fruits and
vegetables. Water was available ad libitum. Monkeys were sub-
jected to clinical inspection of lymphatic ganglia, skin, and
respiratory, digestive and nervous systems. They did not show
any signs of pain or distress at any time during the study, and all
results were reported and records maintained in accordance with
IPR and Kenyan Guidelines for animal used in research. IPR follows
international guidelines for use of animals in biomedical research
as it is a World Health Organization Collaborating Centre and has
statutory registration with the NIH-Ofﬁce of Laboratory Animal
Welfare, in addition to local and African wide recognition as a
Centre of Excellence in preclinical studies. The rectal temperature
and body weight in all animals were assessed by the veterinary
staff. Clinical biochemistry was performed on animals every
month, to avoid additional stress to the animals. All immuniza-
tions and blood extractions were performed using ketamine
hydrochloride, 10 mg/kg body weight, and all efforts were made
to minimize suffering.
All animals were screened for previous exposure to dengue
virus by enzyme-linked immunosorbent assay (ELISA) and PRNT.
Animals were considered negative when the anti-DENV IgG titers
and PRNT titers were less than 1/50 and 1/10, respectively.
Recombinant protein and in vitro aggregation reaction
The design, cloning, expression and puriﬁcation of the recom-
binant capsid protein from DENV-2 were previously described
(Lazo et al., 2007; Lopez et al., 2009). The parental strain used was
DENV-2 Jamaica 1409 American/Asian genotype (Deubel et al.,
1988).
NLPs-2 was assembled in vitro as previously described (Gil
et al., 2012). Brieﬂy, 20 mg of the capsid protein were incubated
with 3.4 mg of single-stranded DNA oligonucleotides of 39 bases
(ODN M39) for a protein:nucleic acid molecular ratio of 3:1 in
assembly buffer (25 mM HEPES, 100 mM KAc, 1.7 mM MgAc, pH
7.4). The reaction mixture was incubated for 30 min at 30 1C and
ﬁnally stored at 4 1C.
ODN M39: ATCGACTCTCGAGCGTTCTCGGGGGACGATCGTCGG-
GGG.
Monkeys immunization and challenge
Six monkeys were ranked by weight, age and sex and then
randomly divided in two groups of three animals each. The
subcutaneous route was used for the administration of the vaccine
formulations.
Group 1: Placebo (8.5 μg of ODN 39 M)
Group 2: 50 mg of NLPs-2
All formulations were prepared using alum at a ﬁnal concen-
tration of 1.44 mg/mL. The doses were administered in each group
at days 0, 60, 120 and 180. Each dose was given in a ﬁnal volume of
0.5 mL. Blood samples were collected at the time of, and 15 days
after each inoculation (days 15, 75, 135 and 195). Serum from
clotted blood was stored at 20 1C.
Thirty days after receiving the last dose, monkeys were sub-
cutaneously inoculated in the upper arms with 103 pfu of DENV-2
(SB8553). Blood was collected daily for 10 days to detect viremia.
The presence of virus in serum samples was determined by direct
plaque formation on Vero cells as previously described (Valdes
et al., 2009).
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Measurement of humoral immune response
The anti-DENV IgG antibodies induced by immunization were
monitored by ELISA. Brieﬂy, ﬂat-bottomed 96-well plates (Costar,
USA) were coated with the monoclonal antibody 4G2 (5 μg/mL),
which recognizes the ﬂavivirus E protein (Kaufman et al., 1987), in
coating buffer (0.16% Na2CO3, 0.29% NaHCO3, pH 9.5) during 2 h at
37 1C. Three washes with PBS containing 0.05% Tween 20 (v:v)
(Merck, Germany) (PBS-T) were completed after each step. Plates
were blocked with 2% bovine serum albumin (BSA) during 1 h at
37 1C, and then incubated overnight at 4 1C with a saturating
concentration of DENV antigen and mock antigen in separate
wells. Serially diluted samples from sera (starting at 1:50) were
incubated 1 h at 37 1C with either DEN or mock antigen. Anti-
monkey IgG-peroxidase conjugate (Sigma, USA) was added and
the plates were incubated 1 h at 37 1C. After washing, 0.04%
substrate solution (O-phenilendiamine in buffer 2% Na2HPO4, 1%
citric acid, and 30% H2O2, pH 5.0) were added. The plates were
kept 30 min at room temperature and the reaction was stopped
with 12.5% H2SO4. Absorbance was read at 492 nm in a microplate
reader (SensIdent Scan; Merck, Germany). Titers were deﬁned as
the dilution of serum giving twice the absorbance value of the
negative control serum.
To detect the anti-capsid IgG antibodies, ﬂat-bottomed 96-well
plates (Costar, USA) were coated 2 h at 37 1C with dengue-2 capsid
protein (5 mg/mL) in coating buffer. Three washes with PBS
containing 0.05% Tween 20 (v:v) (Merck, Germany) (PBS-T) were
completed after each step. Plates were blocked with 2% bovine
serum albumin (BSA) during 1 h at 37 1C. Serially diluted samples
from sera (starting at 1:50) were incubated 1 h at 37 1C with either
DEN or mock antigen. The detection was similar to the assay
described above.
The functionality of the antibodies was measured by PRNT
(Morens et al., 1985) in Vero cells. The end point neutralization
titer was calculated as the highest serum dilution tested that
reduced the number of plaques by at least 50% (PRNT50). The
monoclonal antibody 4G2 was used as positive control (Kaufman
et al., 1987).
Measurement of cellular immune response
Monkey blood was obtained at days 180 and 195, 210 and 240.
Peripheral blood mononuclear cells (PBMC) were isolated as
previously described (Valdes et al., 2010).
Spleen cells were obtained in aseptic conditions and erythro-
cytes were lysed by adding NH4Cl 0.83% solution. Cells were
washed twice with PBS 2% FBS (PAA Laboratories, Ontario, Canada)
and resuspended at 2106 cells/mL in RPMI 1640 medium (Sigma
Aldrich) supplemented with 100 U/mL penicillin, 100 μg/mL strep-
tomycin (Gibco, UK), 2 mM glutamine (Gibco, UK), 5105 M 2-
mercaptoethanol (Sigma St. Louis, MO) and 5% FBS. Finally
2.5105 cells/well were cultured in 96 well round bottom plates
with the antigens (2.5104 pfu of DENV-2 antigen or mock
preparation). Concanavalin A (Sigma St. Louis, MO) was used as a
positive control. In all experiments three wells were plated for
each antigen. After 4 days of culture, culture supernatants were
collected and stored at 20 1C.
The culture supernatants were analyzed in duplicate for inter-
feron gamma (INF-γ) concentrations by ELISA using monoclonal
antibody pairs (Mabtech INF-γ; Sweden) and the protocol recom-
mended by the manufacturer.
in vitro cytotoxicity assay
Cytotoxic activity was determined in a 48 h in vitro lactate
dehydrogenase assay (Roche, USA) using 2105 spleen cells, from
the immunized animals, co-cultured with 103 pfu DENV antigen.
Percentage of speciﬁc lysis was calculated as [(experimental
releasespontaneous release)/(maximum releasespontaneous
release)]100. Maximum release was obtained by adding 1%
Triton X-100 to cells, and spontaneous release was determined
by incubating the cells with medium alone.
Statistical analysis
The analysis of viremia in monkeys was compared using one-
tailed unpaired t test with Welch's correction. Viremia was
compared between both groups per day, using three independent
experiments. With this assumption (nine values of viral load for
each group per days), the normal distribution of the data was
conﬁrmed by the D’Agostino & Pearson omnibus normality test. In
both cases, GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA) was used.
Acknowledgments
The authors thank to James Ndungú and Prisilla Kimiti from the
IPR, Kenya, for his technical support in the manipulations of the
animals. The authors thank Dr. Ricardo Silva and Dr. Jorge Martín
from CIGB for their critical reading and useful comments in the
revision of the manuscript. We also thank Dr. Jamilet Miranda
Navarro and Dr. Yasser Perera Negrín for the statistical analysis of
data. This investigation received ﬁnancial support from the Cuban
Program for Dengue Vaccine Development.
References
Baulu, J., Evans, G., Sutton, C., 2002. Pathogenic agents found in Barbados
Chlorocebus aethiops sabaeus and in Old World Monkeys commonly used in
biomedical research. Lab. Primate Newslett. 41, 4–6.
Blaney Jr., J.E., Sathe, N.S., Goddard, L., Hanson, C.T., Romero, T.A., Hanley, K.A.,
Murphy, B.R., Whitehead, S.S., 2008. Dengue virus type 3 vaccine candidates
generated by introduction of deletions in the 30 untranslated region (30-UTR) or
by exchange of the DENV-3 30-UTR with that of DENV-4. Vaccine 26, 817–828.
Clarke, D.H., Casals, J., 1958. Techniques for hemagglutination and
hemagglutination-inhibition with arthropod-borne viruses. Am. J. Trop. Med.
Hyg. 7, 561–573.
Coe, C.L., Savage, A., Bromley, L.J., 1992. Phylogenetic inﬂuences on hormone levels
across the primate order. Am. J. Primatol. 28, 81–100.
Deubel, V., Kinney, R.M., Trent, D.W., 1988. Nucleotide sequence and deduced
amino acid sequence of the nonstructural proteins of dengue type 2 virus,
Jamaica genotype: comparative analysis of the full-length genome. Virology
165, 234–244.
Fu, J., Tan, B.H., Yap, E.H., Chan, Y.C., Tan, Y.H., 1992. Full-length cDNA sequence of
dengue type 1 virus (Singapore strain S275/90). Virology 188, 953–958.
Gagnon, S.J., Ennis, F.A., Rothman, A.L., 1999. Bystander target cell lysis and cytokine
production by dengue virus-speciﬁc human CD4(þ) cytotoxic T-lymphocyte
clones. J. Virol. 73, 3623–3629.
Gagnon, S.J., Zeng, W., Kurane, I., Ennis, F.A., 1996. Identiﬁcation of two epitopes on
the dengue 4 virus capsid protein recognized by a serotype-speciﬁc and a panel
of serotype-cross-reactive human CD4þ cytotoxic T-lymphocyte clones. J. Virol
70, 141–147.
Gil, L., Bernardo, L., Pavon, A., Izquierdo, A., Valdes, I., Lazo, L., Marcos, E., Romero, Y.,
Guzman, M.G., Guillen, G., Hermida, L., 2012. Recombinant nucleocapsid-like
particles from dengue-2 induce functional serotype-speciﬁc cell-mediated
immunity in mice. J. Gen. Virol. 93, 1204–1214.
Gil, L., Lopez, C., Blanco, A., Lazo, L., Martin, J., Valdes, I., Romero, Y., Figueroa, Y.,
Guillen, G., Hermida, L., 2009. The cellular immune response plays an
important role in protecting against dengue virus in the mouse encephalitis
model. Viral Immunol. 22, 23–30.
Gunther, V.J., Putnak, R., Eckels, K.H., Mammen, M.P., Scherer, J.M., Lyons, A., Sztein,
M.B., Sun, W., 2011. A human challenge model for dengue infection reveals a
possible protective role for sustained interferon gamma levels during the acute
phase of illness. Vaccine 29, 3895–3904.
Guy, B., Guirakhoo, F., Barban, V., Higgs, S., Monath, T.P., Lang, J., 2010. Preclinical
and clinical development of YFV 17D-based chimeric vaccines against dengue,
West Nile and Japanese encephalitis viruses. Vaccine 28, 632–649.
Halstead, S.B., 2013. Identifying protective dengue vaccines: guide to mastering an
empirical process. Vaccine 31, 4501–4507.
Higley, J.D., Kings, S.T.J., Hasert, M.F., Champoux, M., Soumi, S.J., Linnoila, M., 1996.
Stability of interindividual differences in serotonin function and its relationship
L. Gil et al. / Virology 456-457 (2014) 70–76 75
to severe aggression and competent social behavior in rhesus macaque females.
Neuropsychopharmacology 14, 67–76.
Jones, C.T., Ma, L., Burgner, J.W., Groesch, T.D., Post, C.B., Kuhn, R.J., 2003. Flavivirus
capsid is a dimeric alpha-helical protein. J. Virol. 77, 7143–7149.
Kaufman, B.M., Summers, P.L., Dubois, D.R., Eckels, K.H., 1987. Monoclonal anti-
bodies against dengue 2 virus E-glycoprotein protect mice against lethal
dengue infection. Am. J. Trop. Med. Hyg. 36, 427–434.
Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z.K.,
Endres, S., Krieg, A.M., Hartmann, G., 2001. Identiﬁcation of CpG oligonucleo-
tide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic
cells. Eur. J. Immunol. 31, 2154–2163.
Kuhn, R.J., Zhang, W., Rossmann, M.G., Pletnev, S.V., Corver, J., Lenches, E., Jones, C.
T., Mukhopadhyay, S., Chipman, P.R., Strauss, E.G., Baker, T.S., Strauss, J.H., 2002.
Structure of dengue virus: implications for ﬂavivirus organization, maturation,
and fusion. Cell 108, 717–725.
Kyle, J.L., Harris, E., 2008. Global spread and persistence of dengue. Annu. Rev.
Microbiol. 62, 71–92.
Lazo, L., Gil, L., Lopez, C., Valdes, I., Blanco, A., Pavon, A., Romero, Y., Guzman, M.G.,
Guillen, G., Hermida, L., 2012. A vaccine formulation consisting of nucleocapsid-
like particles from Dengue-2 and the fusion protein P64k-domain III from
Dengue-1 induces a protective immune response against the homologous
serotypes in mice. Acta Trop. 124, 107–112.
Lazo, L., Gil, L., Lopez, C., Valdes, I., Marcos, E., Alvarez, M., Blanco, A., Romero, Y.,
Falcon, V., Guzman, M.G., Guillen, G., Hermida, L., 2010. Nucleocapsid-like
particles of dengue-2 virus enhance the immune response against a recombi-
nant protein of dengue-4 virus. Arch. Virol. 155, 1587–1595.
Lazo, L., Hermida, L., Zulueta, A., Sanchez, J., Lopez, C., Silva, R., Guillen, G., Guzman,
M.G., 2007. A recombinant capsid protein from Dengue-2 induces protection in
mice against homologous virus. Vaccine 25, 1064–1070.
Lobigs, M., Mullbacher, A., Lee, E., 2004. Evidence that a mechanism for efﬁcient
ﬂavivirus budding upregulates MHC class I. Immunol. Cell Biol. 82, 184–188.
Lopez, C., Gil, L., Lazo, L., Menendez, I., Marcos, E., Sanchez, J., Valdes, I., Falcon, V.,
de la Rosa, M.C., Marquez, G., Guillen, G., Hermida, L., 2009. in vitro assembly of
nucleocapsid-like particles from puriﬁed recombinant capsid protein of
dengue-2 virus. Arch. Virol. 154, 695–698.
McGee, C.E., Lewis, M.G., Claire, M.S., Wagner, W., Lang, J., Guy, B., Tsetsarkin, K.,
Higgs, S., Decelle, T., 2008. Recombinant chimeric virus with wild-type dengue
4 virus premembrane and envelope and virulent yellow fever virus Asibi
backbone sequences is dramatically attenuated in nonhuman primates. J. Infect.
Dis. 197, 693–697.
Morens, D.M., Halstead, S.B., Repik, P.M., Putvatana, R., Raybourne, N., 1985.
Simpliﬁed plaque reduction neutralization assay for dengue viruses by semi-
micro methods in BHK-21 cells: comparison of the BHK suspension test with
standard plaque reduction neutralization. J. Clin. Microbiol. 22, 250–254.
Mukhopadhyay, S., Kuhn, R.J., Rossmann, M.G., 2005. A structural perspective of the
ﬂavivirus life cycle. Nat. Rev. Microbiol. 3, 13–22.
Page, S.L., Goodman, M., 2001. Catarrhine phylogeny: noncoding DNA evidence for
a diphyletic origin of the mangabeys and for a human-chimpanzee clade. Mol.
Phylogenet. Evol. 18, 14–25.
Raaum, R.L., Stemer, K.N., Noviello, C.M., Stewart, C.B., Disotell, T.R., 2005.
Catarrhine primate divergence dates estimated from complete mitochondrial
genomes: concordance with fossil and nuclear DNA evidence. J. Hum. Evol. 48,
237–257.
Sabchareon, A., Wallace, D., Sirvichayakul, C., Limkittikul, K., Chanthavanich, P.,
Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T.A.,
Moureau, A., Saville, M., Bouckenooghe, A., Viviani, S., Tornieporth, N.G., Lang,
J., 2012. Protective efﬁcacy of the recombinant, live-attenuated, CYD tetravalent
dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
Lancet 380, 1559–1567.
Valdes, I., Hermida, L., Gil, L., Lazo, L., Castro, J., Martin, J., Bernardo, L., Lopez, C.,
Niebla, O., Menendez, T., Romero, Y., Sanchez, J., Guzman, M.G., Guillen, G.,
2010. Heterologous prime-boost strategy in non-human primates combining
the infective dengue virus and a recombinant protein in a formulation suitable
for human use. Int. J. Infect. Dis. 14, e377–e383.
Valdes, I., Hermida, L., Martin, J., Menendez, T., Gil, L., Lazo, L., Castro, J., Niebla, O.,
Lopez, C., Bernardo, L., Sanchez, J., Romero, Y., Martinez, R., Guzman, M.G.,
Guillen, G., 2009. Immunological evaluation in nonhuman primates of formula-
tions based on the chimeric protein P64k-domain III of dengue 2 and two
components of Neisseria meningitidis. Vaccine 27, 995–1001.
van der Most, R.G., Murali-Krishna, K., Ahmed, R., Strauss, J.H., 2000. Chimeric
yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the
dengue virus-speciﬁc CD8 T-cell response. J. Virol 74, 8094–8101.
Verthelyi, D., Ishii, K.J., Gursel, M., Takeshita, F., Klinman, D.M., 2001. Human
peripheral blood cells differentially recognize and respond to two distinct CpG
motifs. J. Immunol. 166, 2372–2377.
Weiskopf, D., Angelo, M.A., de Azeredo, E.L., Sidney, J., Greenbaum, J.A., Fernando, A.N.,
Broadwater, A., Kolla, R.V., De Silva, A.D., de Silva, A.M., Mattia, K.A., Doranz, B.J.,
Grey, H.M., Shresta, S., Peters, B., Sette, A., 2013. Comprehensive analysis of dengue
virus-speciﬁc response supports and HLA-linked protective role for CD8þ T cells.
Proc. Nat. Acad. Sci. U.S.A. 110, E2046–E2053.
Yauch, L.E., Prestwood, T.R., May, M.M., Morar, M.M., Zellweger, R.M., Peters, B.,
Sette, A., Shresta, S., 2010. CD4þ T cells are not required for the induction of
dengue virus-speciﬁc CD8þ T cell or antibody responses but contribute to
protection after vaccination. J. Immunol. 185, 5405–5416.
Yauch, L.E., Zellweger, R.M., Kotturi, M.F., Qutubuddin, A., Sidney, J., Peters, B.,
Prestwood, T.R., Sette, A., Shresta, S., 2009. A protective role for dengue virus-
speciﬁc CD8þ T cells. J. Immunol. 182, 4865–4873.
Zellweger, R.M., Miller, R., Eddy, W.E., White, L.J., Johnston, R.E., Shresta, S., 2013.
Role of humoral versus cellular responses induced by a protective dengue
vaccine candidate. PLoS Pathog. 9, e1003723.
Zompi, S., Santich, B.H., Beatty, P.R., Harris, E., 2012. Protection from secondary
dengue virus infection in a mouse model reveals the role of serotype cross-
reactive B and T cells. J. Immunol. 188, 404–416.
L. Gil et al. / Virology 456-457 (2014) 70–7676
